Q1 2024 Zoetis Inc Earnings Call Transcript
Key Points
- Zoetis Inc (ZTS) reported a strong first quarter with 12% operational revenue growth and a 15% increase in adjusted net income operationally.
- The U.S. market led with a 16% growth, driven by the launch of the osteoarthritis pain franchise, showcasing strong domestic performance.
- Zoetis Inc (ZTS)'s companion animal portfolio grew by 20% operationally, fueled by the human-animal bond and demand for new products like Librela and Solensia.
- The company's strategic focus on innovation and science-driven products continues to pay off, with significant growth in new and existing markets.
- Zoetis Inc (ZTS) has successfully expanded its market share in the parasiticides category, moving from #5 to #2, driven by products like Simparica and Simparica Trio.
- Despite overall growth, the livestock segment of Zoetis Inc (ZTS) declined by 1% operationally, reflecting some challenges in this category.
- Economic conditions in China and inventory destocking in the U.S. diagnostics sales model change presented headwinds, impacting growth.
- The company faces ongoing competitive pressures, particularly in the dermatology and parasiticides categories, which could affect market share and pricing power.
- Foreign exchange fluctuations continue to pose a risk, with a noted unfavorable impact on financial metrics such as adjusted gross margins.
- Zoetis Inc (ZTS) is navigating a complex global market environment, with geopolitical tensions and economic uncertainty potentially affecting future performance.
Welcome to the First Quarter 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
The presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com. The presentation slides can be managed by you, the viewer, and will not be forwarded automatically.
In addition, a replay of this call will be available approximately 2 hours after the conclusion of the call via dial-in or on the Investor Relations section of zoetis.com.
(Operator Instructions) It is now my pleasure to turn the floor over to Steve Frank. Steve, you may begin.
Thank you, operator. Good morning, everyone, and welcome to the Zoetis First Quarter 2024 Earnings Call. I am joined today by Kristin Peck, our Chief Executive Officer; and Wetteny Joseph, our Chief Financial Officer.
Before we begin, I'll remind you that the slides presented on this call are available on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
